# Histocompatibility & Immunogenetics


## Variability of Luminex Methods -Findings from a Survey of UK NEQAS for H&I Participants


## Felicity May, Tracey Rees, Deborah Singleton & Christopher Darke

## Introduction

In 2016, UK NEQAS for H&I requested detailed information on the Luminex methodology used by participants for its 'HLA Antibody Specificity Analysis' scheme (Scheme 3) . 76 out of the 80 (95.0%) participants responded.

### **Results**





- Bead volumes ranged from 1.5µl to 5µl for LABScreen and from 2.5µl to 40µl for Lifecodes
- □ Serum volumes ranged from 8µl to 20µl for LABScreen and 5µl to 20µl for Lifecodes

#### **Negative Control Sera**

- □ 72.4% (n=55) of participants used the manufacturer's
- □ 9.2% (n=7) used 'in house'
- □ 2.6% (n=2) used no negative control sera
- □ 15.8% (n=12) did not specify

ilCi

#### **Positive Control Sera**

- 81.6% (n=62) used a positive control of which:
- □ 69.4%(n=43) used patients' sera
- □ 85.5%(n=53) included this control in every run.

Ymddiriedolaeth

Velindre NHS Trust

**GIG** Felindre

#### Sample Storage


96.1%(n=73) stored samples before testing, including:

- □ Freezing 82.2% (n=60)
- □ Refrigeration 16.4% (n=12)
- □ Ambient 1.4% (n=1)

72.6% (n=53) routinely stored samples for >48 hours before testing.

#### **Serum Treatment**

79.0% (n=60) used serum treatment, 7.9% (n=6) did not, 13.2% (n=10) did not specify. Methods used are shown below (some labs applied several methods):



#### Wash Steps

All but 2 laboratories followed the manufacturer's incubation times and used the supplied wash buffer.

- □ 65.8% (n=50) removed buffer using a vacuum manifold
- □ 30.3% (n=23) used 'centrifuge, flick and blot'
- □ 1.3% (n=1) used LabXpress
- □ 2.6% (n=2) did not specify

#### **Data Analysis**

- G9.7% (n=53) used 'HLA Fusion',
- □ 17.1% (n=13) used MatchIT,
- □ 7.9% (n=6) used both HLA Fusion' and MatchIT
- □ 5.3% (n=4) used 'HLA Fusion' with other software.

Minimum positive control bead MFI varied from 400 - 10000 and the criteria for high background ranged from MFIs of 300 - 1500.

## Comment

These findings indicate disturbing variations in Luminex practices.

## **Further Information**

Full information on all UK NEQAS for H&I schemes is available at **www.neqashandi.org.uk** or contact the Schemes' Manager at **ukneqashandi@wales.nhs.uk** 

WELSH TRANSPLANTATION AND IMMUNOGENETICS LABORATORY

